Paper40565299
Bispecific Antibodies in Solid Tumors: Advances and Challenges.
Shan KS and 7 others. Int J Mol Sci, 2025. Cited by 23 papers, by iCite.
Cite this record
ConductScience Library. Bispecific Antibodies in Solid Tumors: Advances and Challenges. Papers, record 40565299. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/40565299
- Sources
- 11 sources
- Release
- papers-2026-11-12-0.1.0
Paper
PubMed's record of the paper, with iCite's citation figures. No abstract is shown.
Topics6
NLM's MeSH indexing of the paper, its major topics first.
| MeSH term | Major |
|---|---|
| Antibodies, Bispecific | Major topic |
| Neoplasms | Major topic |
| Immunotherapy | Major topic |
| Antineoplastic Agents, Immunological | Major topic |
| Humans | |
| Animals |
Source PubMed
References119
The papers the reference list in PubMed's record names, those in our copy of PubMed, in the list's order.
| Order | PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|---|
| 1 | 27666558 | The Binding Site Barrier Elicited by Tumor-Associated Fibroblasts Interferes Disposition of Nanoparticles in Stroma-Vessel Type Tumors. | ACS Nano | 2016 | https://conductscience.org/library/papers/27666558 | PubMed |
| 2 | 38906157 | Neoadjuvant SHR-1701 with or without chemotherapy in unresectable stage III non-small-cell lung cancer: A proof-of-concept, phase 2 trial. | Cancer Cell | 2024 | https://conductscience.org/library/papers/38906157 | PubMed |
| 3 | 39614368 | The first-in-class bispecific antibody IBI318 (LY3434172) targeting PD-1 and PD-L1 in patients with advanced tumors: a phase Ia/Ib study. | J Hematol Oncol | 2024 | https://conductscience.org/library/papers/39614368 | PubMed |
| 4 | 38030788 | PRAME induces genomic instability in uveal melanoma. | Oncogene | 2024 | https://conductscience.org/library/papers/38030788 | PubMed |
| 5 | 27757559 | 5T4 oncofoetal antigen: an attractive target for immune intervention in cancer. | Cancer Immunol Immunother | 2017 | https://conductscience.org/library/papers/27757559 | PubMed |
| 6 | 35439029 | Phase Ib Study of Navicixizumab Plus Paclitaxel in Patients With Platinum-Resistant Ovarian, Primary Peritoneal, or Fallopian Tube Cancer. | J Clin Oncol | 2022 | https://conductscience.org/library/papers/35439029 | PubMed |
| 7 | 34315767 | Phase I Open-Label Study Evaluating the Safety, Pharmacokinetics, and Preliminary Efficacy of Dilpacimab in Patients with Advanced Solid Tumors. | Mol Cancer Ther | 2021 | https://conductscience.org/library/papers/34315767 | PubMed |
| 8 | 38252906 | Consensus recommendations on the management of toxicity associated with CD3×CD20 bispecific antibody therapy. | Blood | 2024 | https://conductscience.org/library/papers/38252906 | PubMed |
| 9 | 32641320 | Bintrafusp alfa, a bifunctional fusion protein targeting TGF-β and PD-L1, in advanced squamous cell carcinoma of the head and neck: results from a phase I cohort. | J Immunother Cancer | 2020 | https://conductscience.org/library/papers/32641320 | PubMed |
| 10 | 34922633 | Recent advances and challenges of bispecific antibodies in solid tumors. | Exp Hematol Oncol | 2021 | https://conductscience.org/library/papers/34922633 | PubMed |
| 11 | 36071036 | Combination of T cell-redirecting bispecific antibody ERY974 and chemotherapy reciprocally enhances efficacy against non-inflamed tumours. | Nat Commun | 2022 | https://conductscience.org/library/papers/36071036 | PubMed |
| 12 | 36793213 | An optimized IgG-based B7-H3xCD3 bispecific antibody for treatment of gastrointestinal cancers. | Mol Ther | 2023 | https://conductscience.org/library/papers/36793213 | PubMed |
| 13 | 3798106 | Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene. | Science | 1987 | https://conductscience.org/library/papers/3798106 | PubMed |
| 14 | 39864547 | Preventing Infusion-Related Reactions With Intravenous Amivantamab-Results From SKIPPirr, a Phase 2 Study: A Brief Report. | J Thorac Oncol | 2025 | https://conductscience.org/library/papers/39864547 | PubMed |
| 15 | 35653122 | SHR-1701, a Bifunctional Fusion Protein Targeting PD-L1 and TGFβ, for Recurrent or Metastatic Cervical Cancer: A Clinical Expansion Cohort of a Phase I Study. | Clin Cancer Res | 2022 | https://conductscience.org/library/papers/35653122 | PubMed |
| 16 | 37286303 | Tebentafusp in combination with durvalumab and/or tremelimumab in patients with metastatic cutaneous melanoma: a phase 1 study. | J Immunother Cancer | 2023 | https://conductscience.org/library/papers/37286303 | PubMed |
| 17 | 38339430 | Claudin 18.2 as a New Biomarker in Gastric Cancer-What Should We Know? | Cancers (Basel) | 2024 | https://conductscience.org/library/papers/38339430 | PubMed |
| 18 | 36343381 | The Bispecific Tumor Antigen-Conditional 4-1BB x 5T4 Agonist, ALG.APV-527, Mediates Strong T-Cell Activation and Potent Antitumor Activity in Preclinical Studies. | Mol Cancer Ther | 2023 | https://conductscience.org/library/papers/36343381 | PubMed |
| 19 | 32934330 | Exploring the NK cell platform for cancer immunotherapy. | Nat Rev Clin Oncol | 2021 | https://conductscience.org/library/papers/32934330 | PubMed |
| 20 | 37263673 | Phase I trial of KN046, a novel bispecific antibody targeting PD-L1 and CTLA-4 in patients with advanced solid tumors. | J Immunother Cancer | 2023 | https://conductscience.org/library/papers/37263673 | PubMed |
Cited by21
The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 23 citations.
| PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|
| 42980888 | Advancing CLDN18.2-Targeted Therapies in Pancreatic Cancer: Current Clinical Development and Therapeutic Opportunities. | Curr Treat Options Oncol | 2026 | https://conductscience.org/library/papers/42980888 | PubMed |
| 42881857 | Molecularly Guided Therapy and the Tumor Microenvironment in Advanced Cholangiocarcinoma: Current Evidence and Emerging Strategies Targeting FGFR2, HER2, and IDH1 with Pemigatinib, Zanidatamab, and Ivosidenib. | J Clin Med | 2026 | https://conductscience.org/library/papers/42881857 | PubMed |
| 42463770 | Multiparatopic antibodies overcome tyrosine kinase inhibitor resistance by inducing lysosomal degradation of EGFR mutants. | Oncogene | 2026 | https://conductscience.org/library/papers/42463770 | PubMed |
| 42358825 | A New Paradigm of Bispecific Antibodies in Clinical Management of Gastrointestinal Cancers. | Oncol Res | 2026 | https://conductscience.org/library/papers/42358825 | PubMed |
| 42344894 | Decoding the landscape of bispecific antibodies in breast cancer: insights from a comprehensive trial analysis. | Front Immunol | 2026 | https://conductscience.org/library/papers/42344894 | PubMed |
| 42301527 | B7 homolog 3-targeted CAR-T cells secreting EGFR T-cell engagers for improved control of glioblastoma progression. | Mol Biomed | 2026 | https://conductscience.org/library/papers/42301527 | PubMed |
| 42292353 | Efficacy and safety of cadonilimab for malignant solid tumor treatment: a systematic review and meta-analysis. | Front Immunol | 2026 | https://conductscience.org/library/papers/42292353 | PubMed |
| 42290048 | [Chinese Expert Consensus on Delta-like Ligand 3-T Cell Engager Therapy for SCLC]. | Zhongguo Fei Ai Za Zhi | 2026 | https://conductscience.org/library/papers/42290048 | PubMed |
| 42194027 | Antibody-Drug Conjugates Beyond HER2 in Non-Small Cell Lung Cancer (NSCLC): Mechanisms, Emerging Targets, and Future Directions. | Biomolecules | 2026 | https://conductscience.org/library/papers/42194027 | PubMed |
| 42074315 | Novel Insights into the Role of circRNAs in Cancer Immunotherapy Resistance and Clinical Implications. | Int J Mol Sci | 2026 | https://conductscience.org/library/papers/42074315 | PubMed |
| 41562776 | Antibody-Based Therapeutics in Breast Cancer: Clinical and Translational Perspectives. | Antibodies (Basel) | 2025 | https://conductscience.org/library/papers/41562776 | PubMed |
| 41465586 | Glioblastoma-A Contemporary Overview of Epidemiology, Classification, Pathogenesis, Diagnosis, and Treatment: A Review Article. | Int J Mol Sci | 2025 | https://conductscience.org/library/papers/41465586 | PubMed |
| 41355740 | Functional NK engagers from OmniClic, a common light-chain platform producing fully human-sequence antibodies in a chicken host species. | MAbs | 2025 | https://conductscience.org/library/papers/41355740 | PubMed |
| 41262250 | Bispecific immunotherapy based on antibodies, T-cell receptors, and aptamers: mechanisms of action, adverse effects, and future perspectives. | Front Immunol | 2025 | https://conductscience.org/library/papers/41262250 | PubMed |
| 41217689 | Regulatory dynamics of Th17 lymphocytes in oral squamous cell carcinoma: immune modulation and emerging immunotherapies. | Immunol Res | 2025 | https://conductscience.org/library/papers/41217689 | PubMed |
| 41214696 | Recent clinical advances in nonconjugated antibodies and antibody-drug conjugates for colorectal cancer treatment. | Cancer Cell Int | 2025 | https://conductscience.org/library/papers/41214696 | PubMed |
| 41211166 | Bispecific antibodies in the treatment of epithelial ovarian, endometrial, and cervical cancer: an overview of current applications, challenges, and emerging opportunities. | Explor Target Antitumor Ther | 2025 | https://conductscience.org/library/papers/41211166 | PubMed |
| 41179296 | CD47-Targeted Therapy in Cancer Immunotherapy: At a Crossroads of Promise and Challenge. | Oncol Res | 2025 | https://conductscience.org/library/papers/41179296 | PubMed |
| 41136631 | Bispecific antibodies (PD-1/CTLA-4) vs. PD-1 inhibitors with platinum-based chemotherapy±bevacizumab as first-line therapy for persistent, recurrent, or metastatic cervical cancer: a retrospective matched cohort study. | Cancer Immunol Immunother | 2025 | https://conductscience.org/library/papers/41136631 | PubMed |
| 40992760 | Cancer Stem Cells Decide the Fate of Cancer Immunotherapy by Remodeling Tumor Microenvironment. | Cancer Control | 2025 | https://conductscience.org/library/papers/40992760 | PubMed |
Data dates
The date of each source this release read.
- Trials
- 2026-11-12
- Gene search
- 2026-11-11
- Pipelines
- 2026-09-18
None in this release
- Grants
- Trials
- Comments and corrections
- Genes
- Drugs
- Data
Sources 11
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- HGNCCC0
- iCiteCC BY 4.0
- NCBI GenePublic domain (US government)
- NIH RePORTER's grant and paper linksPublic domain
- Open TargetsCC0 1.0
- PMC's ID filePublic domain (US government)
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- HGNCCC0: https://www.genenames.org/about/license/
- iCiteCC BY 4.0
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this paper from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/papers/v1/40565299
GET https://conductscience.org/api/papers/v1/40565299/references?page=2